Core Laboratories Inc outlook and industry position for long-term investors
Core Laboratories Inc (CLB) specializes in oilfield services, focusing on reservoir optimization and production enhancement through laboratory-based evaluation and diagnostic services. The company provides investors with indirect exposure to global oil and gas demand by helping upstream producers analyze and optimize reservoirs and production processes. Its long-term success is tied to the energy industry's need for efficient resource development and the company's ability to maintain technological leadership and adapt to new analytical tools.
CLB - Core Laboratories Inc Options
This page provides a detailed financial overview of Core Laboratories Inc (CLB), an energy oil & gas equipment & services company. It includes key financial metrics such as market capitalization, income, sales, dividend information, and various ratios like P/E and P/S. The report also covers performance metrics, insider and institutional ownership, and analyst recommendations.
Core Laboratories Inc.(NYSE: CLB) dropped from S&P 600 Energy
Core Laboratories Inc. (NYSE: CLB) has been removed from the S&P 600 Energy index, according to a report published on July 1, 2026. This follows its removal from the S&P Composite 1500 CI and S&P 600 CI on the same day. Despite these index changes, the company recently approved a cash dividend payable on June 1, 2026.
CORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") announced the timing of its second quarter 2026 earnings release and conference call. The earnings press release will be issued after market close on July 29, 2026, and the conference call for investors and analysts will be held at 7:30 a.m. CDT / 8:30 a.m. EDT on July 30, 2026. The call will feature discussions by Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, on the company's financial and operational results.
Core Laboratories schedules Q2 2026 earnings call for July 30
Core Laboratories (NYSE: CLB) announced that it will release its second-quarter 2026 earnings after the market closes on July 29, 2026. The company will then host an investor conference call and listen-only webcast on July 30, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT to discuss its financial and operational results. This scheduling update is consistent with Core Laboratories' regular quarterly cadence, with historical data suggesting minimal stock price impact from such announcements.
Price to earnings forward of Core Laboratories Inc. – NYSE:CLB
This article provides the "Price to earnings forward" value for Core Laboratories Inc. (NYSE: CLB). The content is primarily a data point display within a financial platform interface, showing the company's financial metric without further descriptive analysis.
Core Laboratories Inc. Actuals & Estimates (FWB:HJ1)
This article provides an overview of Core Laboratories Inc. (FWB:HJ1) financial actuals and analyst estimates. It details the company's stock forecast, historical prices, revenue, earnings, net income, dividends, and employee count. Key financial figures and future earnings dates are also highlighted.
HJ1 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Core Laboratories Inc. (HJ1) stock, including analyst price targets, historical highs and lows, and upcoming earnings dates. It also details the company's financial performance, such as recent EPS, revenue, net income, EBITDA, and dividend information, alongside common questions about the stock.
HJ1 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Core Laboratories Inc. (HJ1) stock, including analyst price targets, future earnings, and revenue expectations. It details past financial performance, dividends, and key financial metrics like EBITDA. The article also provides answers to frequently asked questions about the company's stock.
Core Laboratories Inc (CLB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Core Laboratories Inc (CLB), detailing its price momentum, support and resistance levels, and key technical indicators. As of June 26, 2026, CLB's price momentum score is 6.58, with the stock trading between a resistance level of $13.32 and a support level of $9.61. The analysis of various indicators and moving averages largely points to a "Sell" signal for the stock.
Core Laboratories Inc. Actuals & Estimates (LS:A3EB9S)
This article provides financial actuals and estimates for Core Laboratories Inc. (A3EB9S) on the LS exchange, offering insights into its income statement, balance sheet, and cash flow. It includes analyst price targets, upcoming earnings dates, recent earnings per share and revenue figures, net income, dividend information, employee count, and EBITDA. The content also answers frequently asked questions about the company's stock and how to trade it.
Core Laboratories Inc (CLB) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Core Laboratories Inc (CLB), detailing its volatility, financial risk, and investment risk. It highlights the company's beta value of 1.13, indicating higher sensitivity to market movements compared to the S&P 500. The report also presents various financial metrics such as VaR, maximum drawdown, volatility, Sharpe Ratio, and turnover rates, offering insights into the stock's performance and risk profile within the Professional & Commercial Services industry.
Core Laboratories Inc (CLB) Financial Health: Profitability & Balance Sheet Analysis
The article analyzes the financial health of Core Laboratories Inc (CLB), noting its stable financial status and average operating efficiency, with a current financial score of 5.97, ranking 142 out of 161 in its industry. The company's recent quarterly revenue decreased by 1.45% year-over-year, and its net profit saw a significant 412.34% year-over-year decrease. Key financial metrics such as cash and cash equivalents, total assets, and total liabilities are yet to be fully disclosed.
Core Laboratories Inc (CLB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Core Laboratories Inc (CLB) has an earnings forecast score of 6.00, placing it 122nd in its industry. Analysts have set an average price target of $14.00 for CLB, with a "Hold" rating based on the assessments of three analysts. The company's expected revenue for the next quarter is $129.12 million, and its next quarter's EPS is projected to be $0.12.
Core Laboratories Inc (CLB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Core Laboratories Inc (CLB), listing its major institutional holders such as Ariel Investments, LLC, BlackRock Institutional Trust Company, N.A., and Disciplined Growth Investors, Inc. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings. Additionally, it lists ETFs with significant allocations to CLB.
Core Laboratories Inc (CLB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Core Laboratories Inc (CLB), separating its revenue generation by business segments and geographical regions. It shows that services account for 75.86% of its revenue, while product sales make up 24.14%. Regionally, 66.70% of revenue comes from other countries, and 33.30% from the United States.
Core Laboratories Stock - Weekly move and sector check at the end of a soft week
Core Laboratories stock ended the week with a modest gain after a quiet period for oilfield services. The article discusses the stock's performance compared to peers, noting it lagged larger diversified groups but outperformed some smaller niche competitors. It also details how the company generates revenue through reservoir description and production enhancement services.
CLB Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial analysis of Core Laboratories Inc (CLB), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Service revenue accounts for 73.9% of CLB's total sales, while the company maintains a gross margin of 13.10% and a net margin of -0.62%. The analysis also benchmarks CLB's financial performance against industry rivals like WTI and EGY.
Noble Corporation, Valaris, and Core Laboratories Shares Plummet, What You Need To Know
Shares of Noble Corporation, Valaris, and Core Laboratories plummeted after oil prices extended their decline, with Brent crude falling below $80 per barrel. This drop is attributed to the Iran peace deal removing the risk premium from oil prices, impacting revenue projections for E&P producers and demand for oilfield services companies. The article highlights that while a significant drop, Core Laboratories' volatility means this move is meaningful but not fundamentally business-altering in the broader context of its stock performance.
Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?
Core Laboratories (CLB) shares have dropped 17.7% in three months, underperforming its industry and the broader energy sector due to geopolitical disruptions in the Middle East, margin compression, and weak North American activity. The company faces financial pressures from rising debt and interest expenses, persistent cost inflation, and limited visibility into recovery. Given its significant valuation premium and ongoing headwinds, a Zacks Rank #4 (Sell) recommendation suggests investors look to better-ranked alternatives like Imperial Oil (IMO), Murphy USA (MUSA), and Marathon Petroleum (MPC).
Core Laboratories Inc stock (NL0015000CZ2): Oilfield services specialist navigates mixed demand afte
Core Laboratories Inc (CLB) has released its latest quarterly figures, providing insights into the volatile oilfield services market. The company specializes in reservoir description and production enhancement services, with revenue tied to global upstream oil and gas activity. Core Laboratories navigates a mixed demand environment, balancing North American shale with international markets, while its performance is influenced by commodity prices, capital spending, and broader economic conditions.
Core Laboratories Inc stock (NL0015000CZ2): shares trade around mid-teens ahead of recent Q1 update
Core Laboratories Inc (CLB) shares are trading around the mid-teens on the New York Stock Exchange, with investors reviewing the company's Q1 2026 revenue of $121.8 million, which slightly exceeded analyst expectations despite a modest year-on-year decline. The company also announced an upcoming cash dividend payment, emphasizing its commitment to shareholder returns. Investors continue to monitor the company's performance, given the cyclical nature of the oilfield services sector.
Core Laboratories (CLB) Among Most Expensive Energy Stocks Under $2B
Core Laboratories (CLB) has been identified as one of the priciest energy stocks under $2 billion, receiving an F valuation grade from GuruFocus. Despite a strong GF Score of 76/100 and good profitability, its P/E ratio of 21.02 suggests overvaluation compared to historical averages and growth challenges. Investors are cautioned to consider these factors given the company's moderate financial strength and low growth rank.
CLB - Core Laboratories Inc Stock Price and Quote
This article provides a detailed stock quote and company profile for Core Laboratories Inc (CLB), an energy sector company specializing in petroleum reservoir analysis. It includes financial data such as market capitalization, income, sales, various ratios, and performance metrics, alongside recent analyst ratings and insider transaction data. The company's business segments and key personnel are also outlined.
Core Laboratories Inc stock (NL0015000CZ2): steady trading on NYSE ahead of next earnings update
Core Laboratories Inc (CLB) shares traded steadily on the NYSE on June 2, 2026, ahead of its next quarterly earnings update. The oilfield service and reservoir analytics group's performance is closely tied to the U.S. energy sector, crude oil prices, and capital spending by exploration and production companies. Investors are awaiting future guidance after the company reported Q1 2026 results in April.
Top Core Laboratories (CLB) Competitors 2026
This article analyzes Core Laboratories (CLB) by comparing it to several competitors in the energy sector: Patterson-UTI Energy (PTEN), Halliburton (HAL), Helmerich & Payne (HP), Magnolia Oil & Gas (MGY), and Nabors Industries (NBR). The comparisons cover various financial metrics including dividends, valuation, earnings, profitability, risk, analyst ratings, and institutional ownership. While Core Laboratories shows strengths in certain areas like net margin and institutional ownership, most competitors generally perform better across a wider range of comparison factors.
How Core Laboratories Inc. (CLB) Affects Rotational Strategy Timing
This article analyzes Core Laboratories Inc. (CLB) and its impact on rotational strategy timing, identifying positive near-term sentiment but a weak mid-term bias within a long-term strength context. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for CLB. The analysis suggests elevated downside risk due to the absence of additional long-term support signals.
How Core Laboratories Inc. (CLB) Affects Rotational Strategy Timing
This article analyzes Core Laboratories Inc. (CLB) through AI-driven quantitative research, identifying short-term positive sentiment, a mid-term weak bias, and long-term strength. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis providing support and resistance levels. The report suggests an elevated downside risk in the absence of additional long-term support signals.
Implied Volatility Surging for Core Laboratories Stock Options
Implied volatility for Core Laboratories Inc. (CLB) stock options is notably high, particularly for the June 18, 2026 $25.00 Call, suggesting that the market anticipates a significant price movement. Despite this, analysts have a negative outlook on the company, with Core Laboratories holding a Zacks Rank #4 (Sell) and recent downward revisions to earnings estimates. This situation may present an opportunity for experienced options traders to sell premium, betting on the stock not moving as much as the implied volatility suggests.
CLB News | CORE LABORATORIES INC (NYSE:CLB)
This page provides the latest news and analysis for Core Laboratories Inc. (NYSE:CLB), including its current stock price and highlights a recent press release from Zacks regarding surging implied volatility for CLB stock options.
Disciplined Growth Investors holds 4.94M CLB shares (NYSE: CLB)
Disciplined Growth Investors, Inc. has disclosed beneficial ownership of 4,937,115 common shares of Core Laboratories Inc. (NYSE: CLB), representing 10.7% of the company's class. This information comes from an amended passive investment disclosure (SCHEDULE 13G/A) filed with the SEC. The filing indicates the investor holds sole voting power over 4,653,638 shares and sole dispositive power over all 4,937,115 shares.
Core Laboratories Shareholders Back Directors, Auditor and Pay
Core Laboratories shareholders re-elected Class I directors Harvey Klingensmith and Curtis Anastasio, ratified KPMG LLP as the independent auditor for fiscal year 2026, and supported the company's executive compensation philosophy at their annual meeting. Despite this backing, TipRanks' AI Analyst "Spark" rates CLB as Neutral due to weak technicals and recent revenue decline, though partially offset by improved leverage and solid margins. The company, an oilfield services provider, helps optimize reservoir performance for the energy industry.
Core Laboratories Inc. Common Stock (NY: CLB)
This article provides an overview of recent news and financial updates related to Core Laboratories Inc. (NYSE: CLB). It includes various news headlines, earnings reports, analyst insights, and stock performance updates for the company, spanning from late 2025 to May 2026. The content highlights the impact of geopolitical events and operational challenges on Core Laboratories' stock and earnings.
Core Laboratories Inc. Common Stock (NY: CLB)
This article provides recent news and market data for Core Laboratories Inc. (CLB), including its current stock price and a list of news headlines related to analyst ratings, earnings call transcripts, and its performance in response to oil market changes. The news covers events between October 2021 and May 2023, highlighting various earnings reports, analyst upgrades/downgrades, and reactions to broader economic and oil industry news.
Core Laboratories shareholders approve director elections and executive compensation
Core Laboratories Inc. shareholders approved all proposals at their recent Annual Meeting, including the re-election of two Class I directors, Harvey Klingensmith and Curtis Anastasio, and the ratification of KPMG LLP as their independent registered public accounting firm. Shareholders also provided advisory approval for the compensation of the company’s named executive officers. These approvals come despite Core Laboratories reporting first-quarter 2026 financial results that missed market expectations.
Core Laboratories Shareholders Back Directors, Auditor and Pay
Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.
Core Laboratories (NYSE: CLB) investors back directors, auditor and pay
Core Laboratories Inc. shareholders approved all three proposals at their Annual Meeting on May 12, 2026. This included the re-election of Class I directors Harvey Klingensmith and Curtis Anastasio, the ratification of KPMG LLP as the independent registered public accountant for 2026, and an advisory vote approving the company's executive compensation program. The meeting saw strong support for these proposals, signifying shareholder confidence in the company's governance and compensation practices.
Number of shareholders of Core Laboratories Inc. – BMV:CLB
The article, titled "Number of shareholders of Core Laboratories Inc. – BMV:CLB," is an incomplete data report from TradingView. It appears to be a stub for financial information regarding Core Laboratories Inc. on the Mexican Stock Exchange, listing headings for "Period," "Value," "Change," and "Change %" but providing no actual data.
Core Laboratories (NYSE:CLB) Downgraded by Wall Street Zen to Sell
Core Laboratories (NYSE:CLB) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, while Weiss Ratings also lowered its view on the stock. Shares of CLB fell 2.3% to $13.15, trading below its 50-day and 200-day moving averages. Despite meeting Q1 earnings estimates with $0.06 EPS, the company's revenue slightly missed expectations and was down 1.4% year-over-year.
Core Laboratories (NYSE: CLB) SVP exercises restricted shares, covers taxes
Core Laboratories SVP Mark Damian Tattoli exercised 250 restricted shares on May 1, 2026. To cover tax obligations, 97 shares were disposed of, leaving him with 27,513.621 directly held shares. The filing also details his indirect holdings and states that multiple restricted share grants vest annually over six years, contingent on continued service.
Core Lab projects Q2 2026 revenue of $123M-$131M and EPS of $0.06-$0.12 amid Middle East disruptions
Core Lab (CLB) has released its projections for the second quarter of 2026, anticipating revenues between $123 million and $131 million and diluted EPS ranging from $0.06 to $0.12. These forecasts come amidst ongoing disruptions in the Middle East, which are impacting the company's financial outlook.
Core Lab projects Q2 2026 revenue of $123M-$131M and EPS of $0.06-$0.12 amid Middle East disruptions
Core Lab (NYSE: CLB) has released its projections for the second quarter of 2026, anticipating revenues between $123 million and $131 million and diluted earnings per share (EPS) ranging from $0.06 to $0.12. These projections are notably lower than current consensus estimates for both revenue and EPS. The company attributes this outlook to ongoing geopolitical disruptions in the Middle East, which are impacting its operational activities and financial performance.
Core Laboratories Earnings Call: Tech Strengths Amid Turmoil
Core Laboratories (CLB) reported a challenging Q1 due to geopolitical issues, weather, and cost inflation, resulting in a 12% sequential revenue drop and significant profitability decline. However, the company highlighted technology successes like GTX and FLOWPROFILER, and its digital data strategy, which positions it for future AI integration. Despite short-term turbulence, Core Lab maintained its shareholder return program, including buybacks and dividends, optimistic about long-term oil demand and its niche oilfield technologies.
Press Release: CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
Core Laboratories (NYSE: CLB) announced its first quarter 2026 financial results, reporting revenue of $169.5 million and diluted EPS of $0.35. The company's operating income for the quarter was $22.4 million, with an operating margin of 13%. Core Lab's Free Cash Flow was $19.4 million, and it maintained its quarterly dividend of $0.10 per share.
Core Laboratories (NYSE:CLB) Shares Down 6.7% - Time to Sell?
Core Laboratories (NYSE:CLB) shares dropped 6.7% on Friday following a decline in trading volume and the stock trading below its 50-day and 200-day moving averages. Analysts maintain a consensus "Hold" rating with an average target price suggesting potential downside. The company met Q1 EPS estimates but saw revenue decline, and has set Q2 guidance.
Core Lab projects Q2 2026 revenue of $123M-$131M and EPS of $0.06-$0.12 amid Middle East disruptions
Core Lab (NYSE: CLB) has issued its financial projections for the second quarter of 2026, anticipating revenue between $123 million and $131 million and diluted EPS ranging from $0.06 to $0.12. This outlook reflects the ongoing disruptions in the Middle East, which are impacting the company's operations and financial performance. Investors will be closely watching how these geopolitical factors influence Core Lab's actual results.
Core Laboratories : 2025 Core Laboratories Annual Report
Core Laboratories has published its 2025 Annual Report, themed "Celebrating 90 Years of Innovation," highlighting its legacy of technological advancements and impact in the energy sector. The report details the company's financial strategies, including maximizing free cash flow and return on invested capital, and its commitment to returning excess capital to shareholders. Despite geopolitical uncertainties and decreased U.S. onshore activity, Core Lab achieved modest year-over-year revenue growth and strengthened its balance sheet by reducing long-term debt.
Core Laboratories Inc. (NYSE:CLB) to Issue Quarterly Dividend of $0.01
Core Laboratories Inc. (NYSE:CLB) declared a quarterly dividend of $0.01 per share, payable on June 1st to shareholders of record on May 11th. This translates to an annual payout of $0.04 and a yield of approximately 0.3%. The company's dividend payout ratio of 4.7% indicates that the dividend is well-covered by earnings, with analysts expecting future earnings to sufficiently cover the annual dividend.
Core Laboratories: Q1 Earnings Snapshot
Core Laboratories Inc. reported a Q1 loss of $789,000, or 2 cents per share, adjusted for non-recurring costs, earnings were 6 cents per share. The energy services company generated revenue of $121.8 million in the first quarter. This financial snapshot was provided by Automated Insights, utilizing data from Zacks Investment Research.
Earnings Flash (CLB) Core Laboratories Inc. Reports Q1 Revenue $121.8M, vs. FactSet Est of $123.0M
Core Laboratories Inc. (CLB) reported its Q1 revenue at $121.8 million, falling short of the FactSet estimate of $123.0 million. The company also posted adjusted EPS of $0.06 per share, which was below FactSet's estimate of $0.09. These results follow a recent cut in Q1 guidance due to the Middle East conflict.
